
Search Clinical Trials
Sponsor Condition of Interest |
---|
Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord In1
University of Alabama at Birmingham
Spinal Cord Injuries
Gut Microbiome
The Investigators will recruit 35 participants with acute SCI (within 6 weeks of injury)
Fasting blood collection and bowel function survey will be conducted 3 times: at baseline
[within 6 weeks of injury], 6, and 12 months after SCI. Stool will be collected for gut
microbiome analysis 3 times. expand
The Investigators will recruit 35 participants with acute SCI (within 6 weeks of injury) Fasting blood collection and bowel function survey will be conducted 3 times: at baseline [within 6 weeks of injury], 6, and 12 months after SCI. Stool will be collected for gut microbiome analysis 3 times. Type: Observational Start Date: Oct 2023 |
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
The purpose of this study is to evaluate the safety, and tolerability and efficacy of
VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic
fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR
modulator therapy. expand
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy. Type: Interventional Start Date: Feb 2023 |
An Accessible and Inclusive Artificial Intelligence Assisted Chronic Disease Self-Management Telehe1
University of Alabama at Birmingham
Disability Physical
Chronic Condition
Chronic Conditions, Multiple
The purpose of this study to pilot test an accessible and inclusive artificial
intelligence (AI)-assisted, individualized, family-focused lifestyle modification
intervention (AI4CHRON) for health-related quality of life for adults with impaired
mobility and chronic medical conditions. expand
The purpose of this study to pilot test an accessible and inclusive artificial intelligence (AI)-assisted, individualized, family-focused lifestyle modification intervention (AI4CHRON) for health-related quality of life for adults with impaired mobility and chronic medical conditions. Type: Interventional Start Date: Feb 2024 |
A Motion Exergaming Approach for Symptom Management: HNC
University of Alabama at Birmingham
Head and Neck Cancer
This overall objective of the RCT is to test an intervention to overcome the PA barriers
for head and neck cancer (HNC) patients during the first 6 months after their treatment.
PAfitME stands for a personalized Physical Activity intervention with fitness graded
Motion Exergames. PAfitME is deliver1 expand
This overall objective of the RCT is to test an intervention to overcome the PA barriers for head and neck cancer (HNC) patients during the first 6 months after their treatment. PAfitME stands for a personalized Physical Activity intervention with fitness graded Motion Exergames. PAfitME is delivered via a tested mix of FaceTime calls and home visits, uses commercially available exergaming platforms (Nintendo Switch). We propose the following specific aims: (1) When compared to an attention control group, determine the effect of PAfitME on fatigue and musculoskeletal pain at week 6, when controlling for age and sex; (2) when compared to an attention control group, determine the effect of PAfitME on functional status and QOL at week 6, when controlling for age and sex; and (3) explore if PA self-efficacy, PA enjoyment, and exergame minutes mediate the effect of PAfitME on fatigue and musculoskeletal pain. This study will evaluate 150 post-treatment (radiation, chemotherapy, or chemoradiation) HNC patients in an RCT with an attention control. For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention, and the attention control group will receive NCI-based survivorship education and exergame equipment. For Aims 1 and 2, using an intention-to-treat framework, we will fit a series of linear mixed effects models with each of the outcome variables. For Aim 3, we will conduct our exploratory analyses in ml_mediation (STATA 15), which will compute direct and indirect effects for multi-level data. Type: Interventional Start Date: Aug 2020 |
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
University of Alabama at Birmingham
Alzheimer Disease
The primary objective of this study is to measure the concentration and the regional
brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in
participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions
between race and vascular risk factors, br1 expand
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study. Type: Interventional Start Date: Apr 2018 |
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Duke University
Rheumatic Joint Disease
Continuation of the CARRA Registry as described in the protocol will support data
collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will
form the basis for future CARRA studies. In particular, this observational registry will
be used to answer pressing questions abo1 expand
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. Type: Observational [Patient Registry] Start Date: Jul 2015 |
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease1
University of Alabama at Birmingham
Decision Making, Shared
Family Caregiving
Chronic Kidney Disease
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the
purpose of this study is to pilot test, an optimization trial approach to develop and
refine the decision partnering skills of persons with stage 4 chronic kidney disease and
their caregivers. Using a 2x2x2 full1 expand
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Using a 2x2x2 full factorial design, 64 dyads (patients and one identified caregiver) will be randomized to receive one or more lay coach-delivered decision partnering training components, based on Pearlin's Stress-Health Model of Family Caregiving and Rini's Social Support Effectiveness theory. The components include: 1) caregiver coaching on effective decision support (1 vs. 3 sessions); 2) caregiver decision support communication training (1 session vs. none); and 3) patient social support effectiveness psychoeducation (yes vs. no). Type: Interventional Start Date: Sep 2024 |
Investigating the Use of TaVNS to Treat Insomnia in Individuals with Breast Cancer (taVNS-insomnia-1
University of Alabama at Birmingham
Breast Cancer
Insomnia
In the present study, the investigators aim to investigate feasibility of utilizing
noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to
address insomnia in patients with stage I-IV breast cancer. expand
In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer. Type: Interventional Start Date: Sep 2023 |
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
T-cell Lymphoma
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients
with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for
an EZH2 mutation as detected by an FDA-approved test and who have received at least 2
prior systemic therapies, and for adul1 expand
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment option. We propose a study to evaluate the safety of tazemetostat in relapsed / refractory peripheral T-cell lymphoma. Type: Interventional Start Date: Sep 2024 |
Improving Age-Related Cognitive Decline with Exercise in Hypertensive Older Adults
University of Alabama at Birmingham
Hypertension
The investigator aims to assess the extent to which a brief exercise intervention
improves systemic growth factor concentrations, reverses loss of systemic vascular
networks and hypertension, and by extension, improves neurocognition. To test the
investigator's hypothesis that increased cardiovascu1 expand
The investigator aims to assess the extent to which a brief exercise intervention improves systemic growth factor concentrations, reverses loss of systemic vascular networks and hypertension, and by extension, improves neurocognition. To test the investigator's hypothesis that increased cardiovascular fitness will correlate with improved vascular density, the investigator proposes the innovative use of retinal density scans. Type: Interventional Start Date: Oct 2021 |
Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy
University of Alabama at Birmingham
Maternal Cytomegalovirus Infections
Cytomegalovirus Congenital
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV)
risk-reduction behavioral intervention will prevent maternal CMV infections during
pregnancy in women. expand
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women. Type: Interventional Start Date: Jan 2021 |
MitraClip REPAIR MR Study
Abbott Medical Devices
Mitral Valve Regurgitation
The objective of this randomized controlled trial (RCT) is to compare the clinical
outcome of MitraClip™ device versus surgical repair in patients with severe primary MR
who are at moderate surgical risk and whose mitral valve has been determined to be
suitable for correction by MV repair surgery b1 expand
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. Type: Interventional Start Date: Jul 2020 |
Providing an Optimized and Empowered Pregnancy for You (POPPY) Aim 3: Randomized Controlled Trial
University of Alabama at Birmingham
Pregnancy Complications
Maternal Distress
Adverse Birth Outcomes
Infant Conditions
The PᵌOPPY study is designed to support the American Heart Association's mission to
improve maternal/infant health outcomes and address inequities in maternal/infant health
care. The P3OPPY Project is one of five projects within the American Heart Association P3
EQUATE Network. The overarching goal1 expand
The PᵌOPPY study is designed to support the American Heart Association's mission to improve maternal/infant health outcomes and address inequities in maternal/infant health care. The P3OPPY Project is one of five projects within the American Heart Association P3 EQUATE Network. The overarching goal of the P3 EQUATE American Heart Association Health Equity Research Network (HERN) is to promote equity in Maternal and Infant Health outcomes by identifying innovative and cost-effective strategies to enhance access to quality health information, care, and experiences during pregnancy, postnatal and postpartum/preconception periods, particularly for Black and under-served populations. Collectively, the investigators will collaborate with pregnant and postpartum individuals and their families, hospitals, and communities to discover ways to reduce racism and social problems that contribute to poor health outcomes. In this trial, 400 non-Hispanic Black participants will be randomized to see if 2 promising interventions (digital health interventions and community health workers) reduce adverse pregnancy outcomes. Type: Interventional Start Date: Aug 2024 |
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in P1
Protara Therapeutics
Lymphatic Malformation
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity,
and efficacy of intracystic injection of TARA-002 in participants 6 months to less than
18 years of age for the treatment of macrocystic and mixed cystic lymphatic
malformations. The Phase 2a safety lead-in, ag1 expand
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart. Type: Interventional Start Date: Oct 2023 |
A Person-Centered Geotagged Social Networking System to Promote Physical Activity in the Community
University of Alabama at Birmingham
Physical Inactivity
Disability Physical
The multilevel socio-ecological barriers to physical activity experienced by people with
physical disabilities cut across structures and systems, community, institutions and
organizations, interpersonal, and individual levels. Several studies have attempted to
understand these barriers and facilita1 expand
The multilevel socio-ecological barriers to physical activity experienced by people with physical disabilities cut across structures and systems, community, institutions and organizations, interpersonal, and individual levels. Several studies have attempted to understand these barriers and facilitators, but to date, no study or system has attempted to systematically resolve these multilevel barriers and capitalize on the potential facilitators that can increase access to exercise and recreation programs, services and facilities for people with disabilities. In RecTech's previous cycle of funding, this void was addressed in a Proof of Concept product called the Activity Inclusion Mapping System (AIMS). AIMS enabled people with disabilities to quickly and precisely identify accessible and usable community-based physical activity resources and services. Based on the positive feedback received at the annual RESNA conference and from our Consumer Research Advisory Committee (CRAC) during preparation of this application, the investigators propose to develop an innovative person-centered geotagged Social Networking System (SNS) based on the social-ecological model of health. The focus of this proposed Proof of Product project is to address multilevel barriers and facilitators associated with community-based leisure time physical activity (LTPA) using crowdsourcing principles for gathering data. The project is targeted to all people with physical disabilities. Type: Interventional Start Date: Jun 2024 |
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants1
Sonya Heltshe
Cystic Fibrosis
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly
effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their
impact on children with cystic fibrosis (CF). expand
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF). Type: Observational Start Date: Nov 2020 |
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
University of Alabama at Birmingham
Diabetic Retinopathy
Results from large clinical trials demonstrate a strong association between lipid
abnormalities and progression of the most common microvascular complication, diabetic
retinopathy (DR). We found that activation of a master regulator of cholesterol
metabolism, the nuclear hormone receptors liver X r1 expand
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell. Type: Observational Start Date: Jan 2018 |
Blue Light Cystoscopy With Cysview® Registry
Photocure
Bladder Cancer
Registry study to gather more information on the current use of Blue Light Cystoscopy
with Cysview (BLCC) in urologists' practices. expand
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices. Type: Observational [Patient Registry] Start Date: Apr 2014 |
Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surge1
University of Alabama at Birmingham
Pelvic Organ Prolapse
The purpose of the study is to evaluate the surgical outcomes of injecting platelet-rich
plasma (PRP) into the vaginal tissue as an adjunct therapy at the time of prolapse
surgery expand
The purpose of the study is to evaluate the surgical outcomes of injecting platelet-rich plasma (PRP) into the vaginal tissue as an adjunct therapy at the time of prolapse surgery Type: Interventional Start Date: Jul 2023 |
Therapeutic Mechanisms of Epidural Spinal Cord Stimulation
University of Alabama at Birmingham
Blood Pressure
Low Back Pain
Hypertension
The purpose of this study in patients undergoing routine care epidural spinal cord
stimulation (SCS) is to determine 1) whether SCS reduces arterial blood pressure (BP) in
patients which chronic low back pain and hypertension, 2) whether higher baseline BP
(i.e., hypertension) predicts reductions i1 expand
The purpose of this study in patients undergoing routine care epidural spinal cord stimulation (SCS) is to determine 1) whether SCS reduces arterial blood pressure (BP) in patients which chronic low back pain and hypertension, 2) whether higher baseline BP (i.e., hypertension) predicts reductions in pain following SCS, and finally 3) whether different SCS waveforms elicits stimulus-evoked compound action potentials (ECAPs) in spinal cord and at the cortex (electroencephalography, and magnetoenchphalography). Type: Interventional Start Date: Aug 2022 |
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Tra1
Arkansas Children's Hospital Research Institute
Hematopoietic Cell Transplant
Solid Organ Transplant
Respiratory Viral Infection
The participants are being asked to take part in this clinical trial, a type of research
study, because the participants are scheduled to receive or have recently received a
hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).
Primary Objective
To determine if pre-transplant scr1 expand
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: - To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors. - To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors . Type: Observational Start Date: Dec 2022 |
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other So1
Arcus Biosciences, Inc.
Clear Cell Renal Cell Carcinoma
Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advanced solid tumor malignancies
and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- casdatifan monotherapy and casdatifan in com1 expand
The purpose of this study is to evaluate the safety and tolerability of: - casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and - casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage Type: Interventional Start Date: Oct 2022 |
Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
University of Alabama at Birmingham
Brain Injuries, Traumatic
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for
the monitoring of traumatic intracranial hematomas. expand
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas. Type: Observational Start Date: Apr 2022 |
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple1
Caribou Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an
allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell
maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the
effectiveness of CB-011 in treating multiple myelom1 expand
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory). Type: Interventional Start Date: Feb 2023 |
ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Seria1
ViTAA Medical Solutions
Abdominal Aortic Aneurysms
This is a Prospective Registry study to collect imaging and clinical data both on
patients with aortic aneurysm disease undergoing serial monitoring and on patients pre
and post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology. expand
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology. Type: Observational [Patient Registry] Start Date: Dec 2021 |
- Previous
- Next